CTLA4 and rheumatoid arthritis: We further show that administration of abatacept (Orencia), an FDA-approved drug for rheumatoid arthritis consisting of the extracellular domain of CTLA-4 fused to human Fc, abrogates these effects by inhibiting B7-1:p75NTR binding.